ARCHIVES

Jane Henney Said Tentative Choice For FDA Commissioner

This article is from The Cancer Letter archive.

Vol. 24 No. 20 | May 22, 1998

Download PDF Visit The Full Archive

Related Articles

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

April 25, 2014

Velcade Addition Can Improve Graft-Versus-Host Outcomes

December 27, 2013

Amgen Website Invites Testimonials, Posts Off-Label Claims By Patients.

November 9, 2007

Lasofoxifene Reduced Breast Cancer Risk In Postmenopausal Osteoporotic Women

November 26, 2010

Mammography Screening For Ages 40-49 Not Supported By Data, NIH Pane! Says

January 31, 1997

Radiation Oncologists Form New College To Address Identity

April 12, 1991